Not Yet Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT07021430

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy

Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy: a Pilot Randomized Controlled Trial

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Interventions Dihydroartemisinin Piperaquine

Updated 5 times since 2025 Last updated: Feb 13, 2026 Started: Apr 30, 2026 Primary completion: Apr 30, 2028 Completion: Apr 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07021430, this EARLY_PHASE1 trial focuses on Malaria Prevention and remains actively recruiting participants. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting EARLY_PHASE1
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting EARLY_PHASE1
Nov 2025 — Jan 2026 [monthly]

Not Yet Recruiting EARLY_PHASE1
Sep 2025 — Nov 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kasese, Uganda